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Acute Intermittent Porphyria: Pathophysiology and 
Treatment 
Ujjaini Khanderia, M.S., Pharm.D. and Arjun Bhattacharya, M.D. 
Acute intermittent porphyria is caused by an inherent error of porphyrin metabolism characterized by a 
deficiency of porphobilinogen deaminase and increased activity of delta-aminolevulinic acid synthase, 
key enzymes necessary for the biosynthesis of heme. During an attack patients may have abdominal 
pain, vomiting, muscle weakness, constipation and neuropsychiatric symptoms. In the majority of 
individuals the disease remains clinically latent throughout life. Various drugs and chemicals, hormones 
and nutritional factors predispose to clinical attacks, probably by inducing hepatic delta-aminolevulinic 
acid synthase. Avoidance of these substances is important in preventing attacks. Screening of family 
members to detect genetic carriers permits precautionary measures. Management of attacks includes 
symptomatic therapy, high carbohydrate intake and intravenous administration of hematin. 
(Pharmacotherapy 1984;4:144-150) 
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Summary 
Acute intermittent porphyria (AIP) is a hereditary 
disorder characterized by an abnormality in the path- 
way of heme biosynthesis, resulting in an overpro- 
duction of precursors of heme. The genetic defect is 
inherited as an autosomal dominant trait. Although 
the exact prevalence is not known, the frequency of 
clinical disease or acute attacks of porphyria is high- 
er in females than in males. Attacks most commonly 
occur between the ages of 20 to 50 years and are 
virtually never seen before puberty. 
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Fundamental Defect 
Heme is synthesized primarily in the liver and the 
bone marrow by a complex pathway that involves a 
series of enzymatic reactions (Figure 1 ).1-3 Starting 
with succinyl CoA and glycine, the first step is the 
formation of delta-aminolevulinic acid (ALA). This re- 
action, catalyzed by the mitochondria1 enzyme delta- 
aminolevulinic acid synthase (ALA synthase), is the 
rate-limiting step in the pathway. Under basal condi- 
tions, the activity of hepatic ALA synthase is low. 
Certain drugs and chemicals, however, can induce 
enzyme activity to levels 50 to 100 times above the 
baseline.- An increased demand for heme can also 
induce hepatic ALA synthase. Heme, the end prod- 
uct of the pathway, represses hepatic ALA synthase 
through a negative feedback effect as shown in Fig- 
ure 1. The activity of ALA synthase is known to be 
limiting for overall heme synthesis in the liver. It is not 
clear if this is also the case in the bone marrow or in 
most other organs. 
Another key enzyme in the pathway is porphobilin- 
ogen deaminase (PBG deaminase), which has fre- 
quently been referred to as uroporphyrinogen I 
synthetase. Recent evidence indicates that PBG 
deaminase does not produce uroporphyrinogen di- 
rectly, but forms a straight-chain tetrapyrrole, hy- 
droxymethylbilane, which then undergoes cycliza- 
tion to produce uroporphyrinogen 1.’ In acute 
intermittent porphyria, PBG deaminase activity is ap- 
proximately 50% of that seen in normal individuals. A 
deficiency of PBG deaminase activity, even to 50% 
of normal, in itself is not sufficient to cause overpro- 
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Figure 1. Heme biosynthetic pathway. 
duction or overexcretion of the porphyrin precursors. 
Also required is an increase in ALA synthase activity, 
coupled with a loss of ALA and porphobilinogen 
(PBG) from hepatocytes and perhaps other cells. 
The disease in the majority (about goo/,) of AIP re- 
mains clinically latent, and patients seldom excrete 
excessive quantities of porphyrin precursors, even 
though deficiency of PBG deaminase is present. It is 
likely that in latent carriers, hepatic ALA synthase 
activity is normal. Drugs, chemicals and factors that 
exacerbate AIP appear to act by inducing ALA synth- 
ase, the rate-controlling enzyme for hepatic heme 
synthesis. In AIP, overproduction of ALA and PBG 
occur in the liver. not in the bone marrow. 
Diagnosis 
Evaluation for AIP should include measurement of 
PBG in urine and PBG deaminase in erythrocytes. 
The Watson-Schwartz tesP is widely used for quali- 
tative determination of PBG in urine. The drawbacks 
with qualitative tests presently available are low sen- 
sitivity and lack of specificity. False positive or nega- 
tive results may occur for a variety of reasons. Uri- 
nary PBG should be determined quantitativelyg when 
AIP is suspected. During an attack, patients excrete 
excessive quantities of PBG in urine; with clinical 
improvement, this usually decreases. In the differen- 
tial diagnosis of acute symptoms that may be due to 
acute porphyria, it is important to measure urinary 
porphobilinogen and to demonstrate by qualitative 
and preferably quantitative methods increases in uri- 
nary PBG concentrations. 
Porphobilinogen deaminase is most conveniently 
measured in erythrocytes.lO- l1 Although in AIP the 
mean enzyme activity is approximately 50% of nor- 
mal, a wide range in PBG deaminase activity has 
been observed, with overlap between normal and 
disease 12* l3 Activity of PBG deaminase in 
patients with AIP may fall within the normal range, 
and more often, within an indeterminate range be- 
tween normal and disease values.13 Assay of the 
deaminase, therefore, totally fails in some cases to 
diagnose the condition. 
Measurement of PBG deaminase in erythrocytes 
is useful for detecting clinically latent gene carriers in 
families of patients with known Alp.’* Because most 
persons with clinically latent disease have normal 
urinary PBG excretion, the enzyme assay is more 
useful for diagnosis. In cases where PBG deaminase 
activity falls into a range that is nondiagnostic, repeat 
assays, quantitative determinations of urinary PBG 
and family genetic analysis are helpful in diagno- 
sis.12.13 
Clinical Manifestations 
Acute intermittent porphyria mimics a variety of 
other disorders and is therefore difficult to diagnose 
on the basis of signs and symptoms alone. The clini- 
cal pattern is quite variable. Although the disease is 
characterized by exacerbations and remissions, a 
great many patients remain asymptomatic through- 
out their lifetime. The most common symptoms in- 
clude abdominal pain, nausea, vomiting, consti- 
pation, back pain, muscle weakness, tachycardia, 
hypertension and ’ a variety of neuropsychiatric 
symptoms.1,2.6. 14.l5 Abdominal pain is the principal 
symptom in approximately 85% or more of the at- 
tacks. Pain may be localized or general, is often col- 
icky and may simulate appendicitis or biliary colic. 
Pain in the back and extremities is common and may 
last from days to months. Motor neuropathy usually 
affects the upper extremities more severely and may 
progress to quadriplegia, dysphagia and respiratory 
paralysis. Impairment of the autonomic nervous sys- 
tem may also occur and result in paralytic ileus. 
Tachycardia is frequently observed during an acute 
attack. Hyponatremia may be a complication and 
has been attributed to the syndrome of inappropriate 
secretion of antidiuretic hormone.16. l7 Hypomagne- 
semia has also been reported and may be severe 
enough to cause tetany.l7< Neuropsychiatric symp- 
toms frequently observed include hysteria, depres- 
sion, agitation, delirium, psychoses and seizures.14 
Pathology 
Postmortem studies on patients with acute inter- 
mittent porphyria indicate that pathologic changes 
may involve multiple areas in the central, peripheral 
and autonomic nervous systems. Both demyelina- 
tion and axonal degeneration of peripheral and auto- 
nomic nerves have been reported in the litera- 
ture.6* 19. 2o Ten Eyck and associates21 demonstrated 
patchy demyelination with extensive degeneration of 
neurons. Autopsy studies by Tschudy et aI6 revealed 
large areas of chromatolysis, vacuolization and de- 
generation of neurons in the supraoptic nucleus of 
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the hypothalamus. The mechanism of central ner- 
vous system involvement underlying the disease is 
not known. Several theories have been suggested to 
explain the chemical mechanism underlying an 
acute attack. It is possible that neurologic distur- 
bances are caused by either a lack of heme in the 
nervous system or a toxic effect from excessive 
amounts of porphyrin precursors and their metabo- 
lites. Several investigators have demonstrated that 
delta-aminolevulinic acid and porphobilinogen, al- 
though not normally present in the cerebrospinal flu- 
id, are detectable during acute episodes of por- 
phyria.6* 22, 23 It is conceivable that certain changes 
occur in the blood-brain barrier during an attack, 
thereby allowing prophyrin precursors to gain entry 
into the central nervous system. It is also likely that 
because of higher plasma concentrations, porphyrin 
precursor concentrations in the cerebrospinal fluid 
become detectable without any change in the blood- 
brain barrier. 
Precipitating Factors 
Acute intermittent porphyria may remain clinically 
latent for indefinite periods of time. The deficiency of 
the enzyme PBG deaminase does not necessarily 
lead to an attack, suggesting that superimposed fac- 
tors come into play in precipitating an episode. Fac- 
tors that are known to exacerbate AIP include a wide 
variety of chemicals and drugs,'- 6. 15* 24-34 drastic 
changes in diet,31.35 starvation, bacterial and viral 
infections, certain endogenous hormones, onset of 
puberty, menstruation and pregnancy. 
Drugs are frequently the cause of acute attacks of 
porphyria. Approximately 68% of the heme synthe- 
sized in the liver is used for the synthesis of cyto- 
chrome P-450, a microsomal enzyme that catalyzes 
mixed-function oxidatiom2 Drugs and chemicals 
that are potent inducers of cytochrome P-450 are 
known to exacerbate AIP. An increase in the require- 
ment for cytochrome P-450 leads to an increased 
demand for heme. This may partially deplete the 
regulatory heme pool and lead to induction of ALA 
synthase, so that the increased demand for heme 
can be met. It is not clear whether the induction of 
ALA synthase is mediated by increased synthesis of 
new enzyme or a stimulation of enzyme activity. Both 
methanisms may be ~perative,~ and it may also oc- 
cur by other mechanisms. A drug or chemical may 
decrease the concentration of hepatic heme by ei- 
ther inhibiting the synthesis of heme or by accelerat- 
ing its destruction. It is also possible that certain 
drugs may act directly on ALA synthase independent 
of changes in heme concentration. Drugs that induce 
cytochrome P-450 or A M  synthase or cause de- 
struction of hepatic heme are best avoided if possi- 
ble. 
All barbiturates, whether alone or in combination 
with other drugs, are notorious for causing exacerba- 
tions of AIP and therefore must be a ~ ~ i d e d . ~ ~ - ~ ~ . ~ ~ a ~ ~  
Sulfonamides and their derivatives have been impli- 
cated in causing serious, even fatal, attacks of por- 
phyria26,27.30 Griseofulvin is a potent inducer of delta- 
aminolevulinic acid synthase and may induce an 
acute a t t a ~ k . ~ ~ . ~ ~ ,  The effect of many drugs on 
porphyria remains unknown. Drugs have been 
screened for their porphyrinogenic potential using 
either animal models or tissue cultures with chick 
embryo liver cell preparations. One must be cautious 
in extrapolating data from animals or tissue cultures 
to the clinical setting because of interspecies differ- 
ences in metabolism. For example, rifampin is a po- 
tent enzyme inducer in man, although this effect is 
not seen in the rat.33.34 Furthermore, patients with 
AIP respond differently to identical porphyrinogenic 
agents. Many agents do not consistently lead to an 
attack. For this reason all drugs should be carefully 
evaluated and merits weighed against risks with their 
use. Patients must be informed about the potential 
dangers of drugs and helped to recognize an im- 
pending attack. Tables 1 and 2 are a compilation of 
drugs reported to be safe or unsafe for use in acute 
intermittent porphyria. Table 3 includes drugs report- 
ed as both safe and unsafe, and over which there is 
still a great deal of controversy. The data have been 
extracted from reports in the worldwide literature, 
and references are cited should readers require 
more extensive information. 
Drastic reduction in caloric intake is also known to 
precipitate acute clinical symptoms of porphyria. In a 
study by Welland and a 6O-8O% reduc- 
tion in daily intake in patients with AIP led to signifi- 
cant increases in urinary ALA and PBG excretion. 
lsocaloric substitution of fat for protein alone or for 
protein and carbohydrate had a similar effect. Addi- 
tion of carbohydrate to the diet was associated with 
decreases in excretion of ALA and PBG. A reciprocal 
relationship was demonstrated between carbohy- 
drate and/or protein intake and porphyrin precursor 
excretion in AIP. A specific link between sex hor- 
mones and the heme pathway at the enzyme level 
was first reported by Grani~k.~' In chick embryo liver 
cell cultures it was demonstrated that estrone, estra- 
diol, progesterone and testosterone stimulated ex- 
cess porphyrin production. Further studies have 
revealed that many C, and C, steroids of the 5- 
beta-hydroxy configuration can stimulate porphyrin 
synthesis. This was related to the induction of ALA 
sy n t hase . 52 
Management 
Prophylaxis is of utmost importance in preventing 
an attack of AIP. The patient must be informed about 
factors that may induce clinical symptoms. Severe 
reductions in caloric intake should be avoided. All 
drugs known to exacerbate the disease and all po- 
tent inducers of cytochrome P-450 should be avoid- 
ed if possible. 
In general, physicians should be extremely con- 
servative in prescribing drugs for patients with acute 
porphyria. If a person with a known underlying genet- 
ic defect requires a drug that has not been tested, 
however, it is ethical to administer the agent cau- 
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Table 1. Porphyrinoaenic Drugs Table 2. Safe Drugs 
Druafsl Referencefsl 
Alpha methyldopa 
Amphetamines 
Aminopyrine 
Antipyrine 
Barbiturates 
Basulfan 
Carbamazepine 
Chlorambucil 
Chloroform 
Chlorpropamide 
Cimetidine 
Clonidine 
Cyclophosphamide 
Cycloserine 
Dimenhydrinate 
Ergot preparations 
Erythromycin 
Ethchlorvynol 
Eucalyptol 
Furosemide 
Glutethimide 
Gold preparations 
Griseofulvin 
Hydantoins (phenytoin, ethotoin, 
mephenytoin) 
Lidocaine and derivatives 
Meprobamate 
Methoxyflurane 
Metoclopramide 
Oral contraceptives 
Oxazolidinediones 
Para-aminosalicylic acid 
Pargyline 
Pentazocine 
Phenylbutazone 
Primidone 
Progesterone 
Pyrazinamide 
Spironolactone 
Steroids 
Succinimides 
Sulfonamides 
Sulfonylureas 
Theophylline 
Tranylcypromine 
Valproate 
26, 27 
27 
26, 27 
26, 27 
15, 24, 26, 27, 30 
30 
26, 27, 30, 36 
30 
26 
26 
39 
30 
40 
27 
24, 27 
27 
30 
6 
27 
27, 30 
41 
27, 30, 31, 32 
30,37, 38 
15, 26, 27, 30, 36, 42 
43 
42 
44 
45 
26, 27, 29, 30 
26, 29 
40 
30, 39 
29, 38, 44 
29, 30, 37 
27, 46 
27, 29, 30, 37 
40 
29, 30 
26, 29 
26, 29, 30, 40 
26, 27, 30 
26, 27, 30, 40 
29, 30, 38 
30 
26, 27, 36, 38, 47 
tiously and with close observation, including serial 
measurements of urinary excretion of A M  and PBG. 
Another important feature is screening family 
members for detecting carriers of AIP, so that pre- 
cautionary measures can be taken to prevent an 
attack. Evaluation should include quantitative deter- 
minations of urinary PBG and erythrocyte PBG de- 
aminase.'. ** l3  
Treatment of the Acute Attack 
Supportive care is necessary to control the acute 
Drug(s) 
Acetazolamide 
Adrenaline 
Aminoglycosides 
Aspirin 
Bromides 
Beta blockers 
Cephalosporins 
Chloral hydrate 
Chlorpheniramine 
Chlorpromazine 
Codeine 
Colchicine 
Diazoxide 
Digitalis 
Diphen hydramine 
Dicumarol 
Droperidol 
Ethambutol 
Ether 
Fentanyl 
Guanethidine 
Heparin 
Ibuprofen 
lndomethacin 
Insulin 
lsoniazid 
Lithium 
Meperidine 
Methadone 
Methenamine mandelate 
Methylphenidate 
Morphine group 
Naproxen 
Neostigmine 
Nitrous oxide 
Nortriptyline 
Pancuronium 
Penicillins 
Penicillamine 
Pethidine 
Prednisolone 
Primaquine 
Procaine and derivatives 
Prochlorperazine 
Promethazine 
Propantheline bromide 
Propoxyphene 
Propranolol 
Prostigmine 
Quinine 
Reserpine 
Streptomycin 
Succinylcholine 
Thiazides 
Thiouracil 
Thyroxine 
Trifluoperazine 
Tubocurarine 
Vitamins A-K 
Reference(s1 
30 
26 
27 
26, 27, 29, 30 
26, 30 
27, 29, 30 
26, 27 
6, 26, 27, 29, 30 
27, 30 
26, 27, 29, 30 
24, 26, 27, 30 
26 
30 
27, 29, 30 
6, 27, 30 
30 
29, 30 
40 
27, 29, 30 . 
43 
26, 27, 29, 30 
26 
26 
26 
26, 30 
40 
26 
24 
24 
27 
30 
24, 43 
26 
27, 29, 30 
27, 29, 30, 44 
27 
43 
27, 29, 30 
26 
43 
26 
27 
27 
26, 27, 30, 40 
26 
26, 29, 30, 40 
26, 29, 30 
26, 27, 30 
27 
27, 30 
6, 27, 30, 40 
29, 30 
26, 27 
27 
27 
26, 27 
26 
27. 30 
26,3a, 43, 44 
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Table 3. Drugs Listed as both Safe and Unsafe 
Drug(s) Reference(s) 
Amitryptiline 26, 27 
Androgens 48 
Chloramphenicol 26, 29, 30 
Chlordiazepoxide 
Chloroquine 26, 27, 29, 37 
Clonazepam 36, 47 
Diazepam 26, 29, 30 
Estrogens 
Ethanol 26, 27, 29, 30 
Fentanyl 29 
Halothane 29, 44 
Hydralazine 26, 30, 39 
lmipramine 
Ketamine 
Nitrofurantoin 29, 30 
Oxazepam 26, 29 
Paraldehyde 26, 30 
Pethidine 29 
Probenecid 26, 30 
Progesterone 
Pyrimethamine 26, 27 
Rifampin 29, 30, 33, 34 
Tetracycline 
26, 27, 29, 30, 42 
26, 27, 29, 30, 49 
25, 26, 29, 30, 38, 42 
26, 27, 29, 30, 44, 50 
26, 27, 29, 30, 49 
6, 26, 27, 29, 30 
symptoms and prevent complications. Hypertension 
and tachycardia can be adequately controlled with 
beta blockers. One patient who was suffering from 
severe hypertension and tachycardia during an at- 
tack was treated with propranolol.= A total of dose of 
284 mg of propranolol was administered intra- 
venously over a period of 18 hours. The acute 
symptoms subsided, and there was a concomitant 
decrease of porphyrin precursors in the urine. Ad- 
ministration of large doses of propranolol, however, 
is a dangerous practice and requires careful monitor- 
ing for hypotension and bradycardia. Bonkowsky 
and TschudyW reported a case in which two doses of 
propranolol 10 mg administered intravenously six 
hours apart was followed by life-threatening hypo- 
tension and bradycardia. Menawat et treated 20 
patients during acute attacks with propranolol ad- 
ministered orally in dosages 'ranging from 20-200 
mg/day. The hypertension and tachycardia were 
adequately controlled within 10 to 15 days of 
therapy. 
Atenolol may be a suitable alternative to proprano- 
101. To date, however, there are no published reports 
of its use in porphyria. Pain can be adequately con- 
trolled with codeine, meperidine or morphine if nec- 
essary. Chlorpromazine is a suitable antiemetic and 
in addition, serves to control the anxiety, neurosis 
and psychosis frequently observed during an attack. 
Promazine and trifluoperazine are also of value in 
management of psychosis. Choosing a drug is a 
problem when seizures complicate the picture be- 
cause anticonvulsants are known to exacerbate an 
attack. All anticonvulsant agents listed under the 
category of unsafe drugs are best avoided if possi- 
ble. Numerous reports seem to indicate that bromide 
may be a useful alternati~e.~~. 47* 56 Careful monitoring 
of serum levels is necessary to avoid the many ad- 
verse toxic effects associated with bromide. 
Carbohydrates are widely used in the treatment of 
acute attacks of AIP. Investigations on the effects of 
carbohydrates on porphyria followed the early find- 
ings that a high carbohydrate intake could prevent 
experimental p~rphyr ia .~~ Welland and associates35 
demonstrated that a high carbohydrate intake low- 
ered urinary porphyrin precursors in AIP. Further 
studies revealed that carbohydrates could block the 
induction of certain enzymes, which was referred to 
as the glucose effectze Tschudy et a157 reported that 
in experimental animal models, large amounts of 
carbohydrates could prevent porphyria by blocking 
the induction of A M  synthase. Glucose feeding is 
known to repress activity of ALA synthase, although 
the mechanism for this repression has not been clari- 
fied.28 In a study by Giger and Meyer,- an inhibitory 
effect of glucose on drug-mediated induction of ALA 
synthase was demonstrated in cultured hepato- 
cytes. The glucose effect was dose-dependent and 
occurred in the complete absence of extrahepatic 
factors such as serum and hormones, implying a 
direct effect on hepatocytes and not necessarily 
mediated through hormonal or other metabolic 
changes. is reported to be as effective as 
glucose in lowering porphyrin precursor excretion. 
During the acute attack, 300 to 500 g of glucose are 
administered per day, either orally or intravenously. 
Response is variable and may range from a dramatic 
recovery to no effect at all. 
Hematin has been investigated in the treatment of 
attacks of Intravenous infusion has been 
found to be effective in reduction of the plasma as 
well as urinary concentrations of ALA and PBG. The 
effect has been more dramatic and clinical response 
to hematin has been more consistent than that seen 
with carbohydrates. In a number of trials, patients 
who were unresponsive to glucose responded to he- 
matin. The optimum dose is not known. Dosages of 
3-4 mg/kg body weight were selected somewhat ar- 
bitrarily and were found to be effective.61, It is not 
known whether smaller doses could also be effective 
clinically. Within 48 hours of administration, plasma 
concentration of porphyrin precursors decreased by 
60-1 00% of prehematin values. Several days after 
the infusions were discontinued, the level gradually 
increased again to reach 50-100% of prehematin 
values, indicating that hematin-induced repression 
of ALA synthase was transient. Clinical response to 
the hematin varied with the severity of the attack. In 
many cases, patients refractory to glucose therapy 
showed a striking improvement clinically.61, 63 As 
many as 2040% of patients showed temporary im- 
provement with relapse within 2 to 14 days. In 15- 
20% there was no apparent benefit from hematin. 
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Hematin, an exogenous source of heme, is pre- 
pared as a lyophilized powder from hemin that is 
crystallized from human red cells, sterilized and 
made pyrogen free prior to administration. The solu- 
tion is administered over 15 to 20 minutes through 
the tubing of a free-flowing saline infusion. Injections 
are given at 12- to 24-hour intervals for 3 to 5 days. 
Intravenously administered hematin is bound to al- 
bumin and hemopexin in the plasma.68, 69 The mean 
concentration of circulating hemopexin, a beta-glob- 
ulin, is only 77 mg/l00 mL70 When the hemopexin 
pool is saturated, hematin binds to albumin from 
where it is slowly released as free hemopexin be- 
comes a~ailable.~’. 72 The heme-hemopexin complex 
is transferred to the liver where hematin is released 
and represses hepatic delta-aminolevulinic acid 
~ y n t h a s e . ~ ~ * ~ * . ~ ~  The clearance of hematin from se- 
rum is biexponential, with a half-life for the first com- 
ponent ranging from 4.5 to 10.6 hours and for the 
second component 28 to 54 Fifty percent to 
70% of an administered dose is converted to bilirubin 
in the liver.74. 75 Exogenously administered hematin 
ultimately appears in the bile as free hematin or bili- 
rubin. 
Few complications have been reported when he- 
matin was administered in recommended doses. 
Dhar et a176 reported a case of transitory renal failure 
following rapid administration of 1,000 mg in a pa- 
tient with acute porphyria. The picture was consis- 
tent with acute tubular necrosis, which resolved after 
hematin was discontinued. It was theorized that this 
adverse effect resulted from significant amounts of 
circulating free hematin. Coagulopathy manifested 
by markedly prolonged prothrombin time, partial 
thromboplastin time and thrombocytopenia has 
been Thrombophlebitis has been report- 
ed at the site of 
Summary 
Acute intermittent porphyria is a hereditary disor- 
der characterized by the deficiency of porphobilino- 
gen deaminase, an enzyme necessary for the bio- 
synthesis of heme. This results in over production, 
accumulation and excessive excretion of porphyrin 
precursors, notably delta-aminolevulinic acid and 
porphobilinogen. The disease is characterized by 
exacerbations and remissions. Many patients re- 
main asymptomatic until a precipitating factor acti- 
vates the disease to provoke an attack. Many drugs 
have been notorious in causing attacks. 
During an acute attack the patient may experience 
abdominal pain, nausea, constipation, muscle weak- 
ness and neuropsychiatric symptoms. Treatment 
involves two therapeautic approaches: use of a high- 
carbohydrate diet and the administration of intrave- 
nous hematin. 
One of the ultimate goals in acute intermittent por- 
phyria is prevention of an attack by avoidance of 
known precipitating factors. It is important for clini- 
cians to be familiar with drugs and other factors that 
have been known to cause acute attacks of por- 
phyria. The patient should be counseled and warned 
about potential danger of drugs so that acute, life- 
threatening attacks of the disease can be prevented. 
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